Market Closed -
Other stock markets
|
Pre-market 00:00:05 | |||
148.4 USD | -0.47% | 146.7 | -1.13% |
06-24 | US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit | RE |
06-24 | J&J: 50M pupils helped through 'Sight for Kids' program | CF |
Business Summary
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Number of employees: 131,900
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Innovative Medicine
64.3
%
| 52,563 | 55.4 % | 54,759 | 64.3 % | +4.18% |
MedTech
35.7
%
| 27,427 | 28.9 % | 30,400 | 35.7 % | +10.84% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
54.5
%
| 48,580 | 51.2 % | 46,444 | 54.5 % | -4.40% |
Europe
24.0
%
| 23,449 | 24.7 % | 20,410 | 24.0 % | -12.96% |
Asia-Pacific, Africa
16.2
%
| 16,789 | 17.7 % | 13,756 | 16.2 % | -18.07% |
Western Hemisphere Excluding United States
5.3
%
| 6,125 | 6.5 % | 4,549 | 5.3 % | -25.73% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 61 | 31/12/88 |
Joseph Wolk
DFI | Director of Finance/CFO | 57 | 31/12/97 |
James Swanson
CTO | Chief Tech/Sci/R&D Officer | 58 | 04/11/19 |
William Hait
CTO | Chief Tech/Sci/R&D Officer | 74 | 31/12/06 |
Jessica Moore
IRC | Investor Relations Contact | - | 31/10/21 |
Michael Bzdak
PRN | Corporate Officer/Principal | - | - |
Jonathan Sheh
PRN | Corporate Officer/Principal | - | - |
Neil Ackerman
PRN | Corporate Officer/Principal | 47 | 31/12/18 |
Caroline Tillett
PRN | Corporate Officer/Principal | 52 | - |
General Counsel | 53 | 31/12/05 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Marillyn Hewson
BRD | Director/Board Member | 70 | 24/04/19 |
D. Davis
BRD | Director/Board Member | 72 | 18/06/14 |
Anne Mulcahy
BRD | Director/Board Member | 70 | 21/10/09 |
Hubert Joly
BRD | Director/Board Member | 64 | 04/12/19 |
Mark McClellan
BRD | Director/Board Member | 60 | 14/10/13 |
Joaquin Duato
CEO | Chief Executive Officer | 61 | 31/12/88 |
Darius Adamczyk
BRD | Director/Board Member | 58 | 14/02/22 |
Eugene Woods
BRD | Director/Board Member | 59 | 11-29 |
Mark Weinberger
BRD | Director/Board Member | 62 | 04/12/19 |
Nadja West
BRD | Director/Board Member | 63 | 02/12/20 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 3,119,799,183 | 2,404,640,893 ( 77.08 %) | 713,120,000 ( 22.86 %) | 77.08 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
KENVUE INC. 9.52% | 182,329,550 | 9.52% | 3,518,960,315 $ |
ILLUMINA, INC. 0.51% | 810,170 | 0.51% | 84,484,528 $ |
2,449,183 | 4.18% | 68,944,501 $ | |
NANOBIOTIX 11.93% | 5,623,816 | 11.93% | 39,591,665 $ |
814,586 | 0.45% | 32,591,586 $ | |
MEIRAGTX HOLDINGS PLC 10.33% | 6,641,064 | 10.33% | 32,541,214 $ |
CONTINEUM THERAPEUTICS, INC. 10.42% | 1,979,173 | 10.42% | 30,320,930 $ |
CVRX, INC. 19.00% | 4,103,430 | 19.00% | 28,518,839 $ |
IDORSIA LTD 5.07% | 9,581,882 | 5.07% | 27,551,264 $ |
357,939 | 0.70% | 23,767,150 $ |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Medical Specialties
| |
Pharmaceuticals: Major
| |
AMO Holdings, Inc.
AMO Holdings, Inc. Electronic ComponentsElectronic Technology Part of Johnson & Johnson, AMO Holdings, Inc. is an American company that manufactures surgical medical devices and lens. The company is located in the US. |
Electronic Components
|
Animas LLC
Animas LLC Medical SpecialtiesHealth Technology Animas LLC manufactures and distributes external insulin pumps for diabetes patients. The company was founded on November 5, 1996 and is headquartered in West Chester, PA. |
Medical Specialties
|
Pharmaceuticals: Major
| |
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. |
Pharmaceuticals: Major
|
Johnson & Johnson Holdco (NA), Inc.
Johnson & Johnson Holdco (NA), Inc. Household/Personal CareConsumer Non-Durables Johnson & Johnson Consumer, Inc. manufactures health and skin care products. It offers wide variety of lotion, moisturizing cream, baby wash, shampoo and conditioner, baby powder and bath, hand and face wipes, soap, baby oil and cologne. The company was founded on March 8, 2016 and is headquartered in Skillman, NJ. |
Household/Personal Care
|
Janssen-Cilag Ltd.
Janssen-Cilag Ltd. Pharmaceuticals: MajorHealth Technology Janssen-Cilag Ltd. provides pharmaceutical products and services. It offers medicines that can treat serious health conditions such as schizophrenia, epilepsy, multiple myeloma, and human immunodeficiency virus/acquired immunodeficiency syndrome. The firm's other key areas of activity include pain management, gastroenterology, fungal infections, women’s health, neurology, and anaemia. The company was founded on October 19, 1971 and is headquartered in High Wycombe, the United Kingdom. |
Pharmaceuticals: Major
|
BioMedical Enterprises, Inc.
BioMedical Enterprises, Inc. Medical SpecialtiesHealth Technology BioMedical Enterprises, Inc. designs, manufactures and markets memory metal implants. It offers products: intramedullary fixation which includes hammerLock and hammerSplint and staple fixation which includes speed, step OSStaple and step BOSS. The company was founded by William Casey Fox in 1991 and is headquartered in San Antonio, TX. |
Medical Specialties
|
Sector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
+54.61% | 815B | |
+44.25% | 654B | |
+20.62% | 337B | |
+10.44% | 302B | |
+18.45% | 247B | |
+2.09% | 229B | |
+13.03% | 219B | |
+8.61% | 171B | |
-4.76% | 159B |
- Stock Market
- Equities
- JNJ Stock
- 0R34 Stock
- Company Johnson & Johnson